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ABSTRACT 
The effects of TYB-2285 and its metabolites (TC-286 and TC-
326) on the adhesion of eosinophils and neutrophils to cultured 
human umbilical vein endothelial cells (HUVEC) stimulated with
tumour necrosis factor α (TNF-α) were investigated. The treat-
ment of HUVEC with TNF-α enhanced eosinophil adhesion in a
dose-dependent manner (1-100U/mL). The adhesion of
eosinophils to TNF-α (100U/mL)-stimulated HUVEC was inhib-
ited by TYB-2285 and its metabolites in a dose-dependent 
manner (10-8-10-5mol/L). These compounds showed stronger 
inhibitory effects than any other anti-allergic drugs, such as dis-
odium cromoglycat (DSCG), ketotifen and tranilast. TYB-2285, 
TC-286 and TC-326 did not inhibit the adhesion of neutrophils 
at the same range (10-8-10-5mol/L).
In our adhesion assay system, eosinophil adhesion to TNF-
α-stimulated HUVEC was blocked by monoclonal antibody
against VLA-4 (anti-VLA-4) but not by that against Mac-1 
(anti-Mac-1). In contrast, neutrophil adhesion was blocked 
by anti-Mac-1, but not by anti-VLA-4. 
 The results of the present study demonstrate that TYB-
2285 and its metabolites selectively inhibit the adhesion of
eosinophils to HJVECs stimulated with TNF-α and also sug-
gest that TYB-2285, TC-286 and TC-326 might block the 
VLA-4/VCAM-1 pathway selectively.
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INTRODUCTION 
Eosinophils are thought to contribute to the pathogenesis of aller-
gic diseases. Allergic patients have increased eosinophil levels in
their circulation and in mucosal tissues, and eosinophils accumu-
late after antigenic challenge in the lungs and nasal airways.1-3 
 The initial phase in the process of eosinophil accumulation is 
the adhesion of eosinophils to endothelial cells, prior to their 
chemotactic transendothelial migration.4,5 This migration requires 
a series of interactions between endothelial cells and the 
eosinophil surface via adhesion molecules. Three major groups 
of adhesion molecules are involved: selectins, integrins and the 
immunoglobulin gene superfamily. P- and E-selectins mediate ini-
tial adhesion, whereas β2-integrin/ICAM-1 and VLA-4/VCAM-1
pathways mediate eosinophil arrest and transendothelial migra-
tion.6 Since VLA-4 expression is restricted to eosinophils and lym-
phocytes, VCAM-1 has been implicated in selective eosinophil 
recruitment characterizing allergic inflammation.7 
 Adhesion of eosinophils to endothelial cells was examined by 
Lamas et al.8 and Kimani et al.9 who documented three mecha-
nisms of adhesion to cultured human umbilical vein endothelial 
cells (HUVEC): (i) adherence of unstimulated eosinophils to rest-
ing HUVEC; (ii) adhesion of eosinophils stimulated by chemo-
tactic factors such as platelet activating factor (PAF) or phorbol 
ester (PMA) to resting HUVEC; (iii) adherence of resting 
eosinophils to HUVEC stimulated by cytokines such as tumor 
necrosis factor (TNF), interleukin-1, (IL-1) or LPS. However, in 
vivo, mediators released at the site of inflammation are likely to 
be rapidly diluted as they enter the blood stream and would 
therefore be unable to stimulate circulating eosinophils. An ini-
tial step may involve adhesion of unstimulated eosinophils to 
activated HUVEC.
 TYB-2285 (3,5-bis (acetoxyacethylamino)-4-chlorobenzoni-
trile) is a novel anti-inflammatory drug which inhibits degranula-
tion of mast cells and basophils primed with IL-3 in vitro10,11 and 
also inhibits the antigen-induced accumulation of eosinophils in 
the airway of sensitized rats (T Tominaga et al., unpubl. data). 
 In the present study, we investigated the effects of TYB-2285 and 
its metabolites (TC-286 and TC-326) on eosinophil adhesion to
HUVEC stimulated with TNF-α, with the aim ofdetermining the role
of TYB-2285 in the inhibition of eosinophil accumulation in rats.
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MATERIALS AND METHODS 
Chemicals
Human recombinant TNF-α was purchased from Promega
Corp. (Madison, WI, USA). Anti-Mac-1 mAb (anti-Mac-1) and
anti-VLA-4β1 integrin mAb (anti-VLA-4) were purchased from
Becton Dickinson (San Jose, CA, USA). TYB-2285 and its 
metabolites (TC-286, 4-chloro-3, 5-bis (hydroxyacetylamino) 
benzonitrile; and TC-326, 3-amino-4-chloro-5 (hydroxyacety-
lamino) benzonitrile) were synthesized at the Pharmaceuticals 
Research Center, Toyobo, Japan. Intal was purchased from 
Fulisawa Pharmaceutical Co. Ltd, Osaka, Japan, and was used 
as disodium cromoglycate (DSCG). Zaditen was purchased from 
Sandoz Ltd, Tokyo, Japan, and was used as ketotifen. Rizaben 
was purchased from Kissei Pharmaceutical Co. Ltd, Nagano, 
Japan, and was used as tranilast. Each drug was dissolved in 
RPMI-1640 (Nissui Pharmaceutical Co. Ltd, Tokyo, Japan), sup-
plemented with 1% foetal calf serum (FCS; Hyclone Laboratories 
Institute, Logan, UT, USA) and diluted to 10-4mol/L (stock solu-
tion). Stock solution was diluted with RPMI-1640 supplemented 
with 1% FCS, to at 10-5-10-8mol/L (final concentration).
Isolation of neutrophils and eosinophils 
Human polymorphonuclear leukocytes were isolated from 
heparinized venous blood of normal donors layered on Mono-
Poly Resolving Medium (ICN Biomedicals Co. Ltd, Tokyo, Japan)
and centrifuged at 400×gfor 10min at roo  temperature. After
centrifugation, red blood cells were removed by hypotonic lysis, 
and the polymorphonuclear leukocytes were used as neutrophils. 
Eosinophils were purified by CD16-negative selection using an 
immunomagnetic beads technique.12 The human polymor-
phonuclear leukocytes layer separated by Mono-Poly Resolving 
Medium was preincubated with anti-CD16 (Oncogene Science
lnc., Uniondale, NY, USA) for 1h at 4℃, followed by incubation
with anti-IgG-coated magnetic beads (Dynal, Oslo, Norway) for 
1h. Magnetically labelled neutrophils were then depleted by 
attachment of the cell suspension to a permanent magnet. 
 Neutrophil and eosinophil purity (based on microscopy of cyto-
centrifugation preparation with Wright-Giemsa was about 95%. 
They were labelled with fluorescent dye as previously described.13 
Briefly, cells were resuspended with PAG buffer (25mmol/L 
PIPES, 110mmol/L NaCI, 5mmol/L KCI) at a concentration of 1
×106cells/mL and incubated with 5μmol/L of 5(-and-6)-car-
boxyfluorescein diacetate, succinimidyle ester (CFSE; Molecular
Probes Inc., Eugene, OR, USA) for 10min at 37℃. Before use in
the adhesion assay, cells were washed twice with RPMI-1640.
Culture of HUVEC 
HUVEC were isolated and cultured according to the method
described by Jaffe et al.14 Cells(1×104)from the third passage
were cultured for 48hat 37℃ in 5%CO2 in 96-well microtitre
plates precoated with collagen in RITC medium (Kyokuto 
Pharmaceutical Industrial Co. Ltd, Tokyo, Japan) supplemented 
with 10% FCS. Cultured cells were used then in the adhesion 
assay.
Expression of adhesion molecules on HUVEC 
sti ulated with TNF-a
HUVEC were incubated with 100U/mL of TNF-α for varying
periods at 37℃ in 5%CO2. Expression of ICAM-1 and VCAM-
1 were determined by enzyme-linked immunosorbent assay
(ELISA), reacting with 100μL of 10μg/mLprimary antibody fol-
lowed by peroxidase-conjugated anti-mouse IgG (Cappel, 
Durham, NC, USA) diluted 1/3000 in RITC medium. Ortho-
phenylene-dia mine was added as a substrate, and absorbance 
at 400nm was measured by a microtiter ELISA reader (Biotek 
Instruments Inc., Burlington, VT, USA).
Adhesion of neutrophils and eosinophils to HUVEC
CFSE-labelled neutrophils or eosinophils(1×105cells/well)
were layered over HUVEC prestimulated with TNF-α. After 20
min incubation, unbound cells were removed by plate inversion 
in RPMI-1640 for 30min at room temperature. After adding 
0.3% Triton X (Nakarai Tesque, Kyoto, Japan) to the adherent 
cells were counted using an automated microplate fluorometer 
(Millipore Corp., Bedford, MA, USA) using 485/22nm excita-
tion and a 530/25nm emission filter.
In the experiments evaluating the effects of the drugs, HUVEC
were incubated with each drug for 6 h during treatment with 100
U/mL TNF-α, and were washed before the adhesion assay.
Neutrophils or eosinophils were also preincubated for 20min 
with each drug, and were then coincubated with HUVEC in the 
presence of each dr g duri g the adhesion assay.
In the experiments evaluating the role of adhesion molecules
in adhesion, neutrophils and eosinophils were preincubated for
20min with mAb against VLA-4 or Mac-1, and were coincu-
bated with HUVEC in the presence of mAb during the 20min
adhesion assay.
 For the experiments evaluating the drugs or mAb, the percent 
of control was calculated according to the following formula: 
Percentage of control=(the percentage adhering to 100U/mL
of TNF-α-treated HUVEC in the presence of drugs or mAb-the
percentage adhering to untreated HUVEC)/(the percentage
adhering to 100U/mLofTNF-α-treated HUVEC inthe absence
of drugs or mAb-the percentage adhering to untreated
HUVEC)×100.
Statistical analysis 
Data was analysed by Student's t-test. Vertical bars in the figures 
show SEM.
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Fig. 1 Time course of ICAM-1 and VCAM-1 expression on HUVEC.
HUVEC were stimulated with 100U/mL TNF-α for the indicated time
periods.
Fig. 3 Effects of TYB-2285 and its metabolites on adhesion of
eosinophils. Eosinophils were allowed to adhere to TNF-α-stimulated
HUVEC in the presence of each drug:
RESULTS 
Adhesion of eosinophils to HUVEC stimulated with
TNF-α
Expression of ICAM-1 and VCAM-1 on HUVEC was markedly
elevated by 100U/mL of TNF-α, reaching a plateau 8h after
treatment with TNF-α (Fig.1).Treatment of HUVEC wi h TNF-α
(1-100U/mL) enhanced eosinophil adhesion in a dose-depen-
dent manner, and adhesion increased significantly (P<0.05)
Fig. 2 Concentration-dependent ffect of TNF-α  on eosinophil-
HUVEC adh sion. HUVEC were incubated for 6h with indicated con-
centrations of TNF-α. Eosinophils were allowed to adhere to
TNF-α-stimulated HUVEC for 20min. Data are the mean±SEM of
two to five subjects. Per cent adhesion to non-treated HUVEC (sponta-
neous) was 4.1±0.5.*P<0.05 vs spontaneous.
following treatment with 100U/mL of TNF-α compared with
adhesion in untreated HUVEC (spontaneous). The percentages
of spontaneous adhesion and 100U/mL of TNF-α-treated
adhesion were 4.5±0.7and 12.5±3.6, respectively (Fig. 2).
Effects of drugs on adhesion of eosinophils to 
TNF-a-treated HUVEC 
Eosinophil adhesion was significantly inhibited by TYB-2285, 
TC-286 and TC-326 in a dose-dependent manner, ranging 
from 10-8 to 10-5mol/L (Fig. 3). DSCG did not inhibit eosinophil 
adhesion in the range 10-8-10-5mol/L. Tranilast did not inhibit 
the adhesion at less than 10-b mol/L, and ketotifen did not 
inhibit the adhesion at less than 10-5mol/L (Fig. 4).
Effects of drugs on the adhesion of neutrophils to 
TNF-a-treated HUVEC 
Neutrophil adhesion was enhanced by treatment of HUVEC with
100U/mL of TNF-α, as was eosinophil adhesion. The percent-
ages of spontaneous adhesion, and 100U/mL of TNF-α-
treated adhesion were 3.0±0.6 and 13.4±2.9, respectively.
Neutrophil adhesion was not inhibited by TYB-2285, TC-286 or 
TC-326 in the range 10-8-10-5mol/L (Fig. 5).
Effects of anti-Mac-1 and anti-VLA-4 on adhesion 
of neutrophils and eosinophils to TNF-a-treated 
HUVEC 
Anti-Mac-1 inhibited neutrophil adhesion but not eosinophil 
adhesion; the reverse was true for anti-VLA-4 (Fig. 6).
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Fig. 4 Effects of anti-allergic drugs on adhesion of eosinophils.
Eosinophils were allowed to adhere to TNF-α-stimulated HUVEC for
20min in the presence of each drug:
Fig. 5. Effects of TYB-2285 and its metabolites on adhesion of neutrophils.
Neutrophils were allowed to adhere to TNF-α-stimulated HUVEC in the
presence of each drug:
DISCUSSION 
There is increasing evidence that eosinophils are important effector 
cells in allergic inflammations. The adhesion of eosinophils to 
endothelial cells is of importance in immune responses, as is the 
infiltration of eosinophils into sites of tissue inflammation. 
Accumulation of eosinophils in allergic reactions is, as yet, largely 
unexplained, however, some groups have offered an explanation 
based on the selective regulation of adhesion molecules.
Fig. 6 Effects of anti-VLA-4
Schleimer et al.15 suggested that IL-4 selectively increased the level 
of VCAM-1 on HUVEC and that its expression was associated with 
the in reased adhesiveness of eosinophils. Lymphocytes from 
allergic patients express mRNA for IL-4, IL-3 and IL-5 (cytokines 
produced by helper 2 T lymphocytes). 16 From this result, Schleimer 
et al. speculated that lymphocytes that infiltrate the site of an aller-
gic eaction produce IL-4 which selectively induces expression of 
VCAM-1  endothelial cells. Mose et al.17 reported that IL-4 treat-
ment specifically promoted the selective trans-endothelial migra-
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tion of eosinophils, and this migration was blocked by antibodies 
to VCAM-1 but not by ICAM-1. This finding agrees with that by 
Schleimer et al. 
 Although these findings were obtained form in vitro studies, in 
vivo studies have also provided evidence that the VLA-4/VCAM-
1 pathway plays an important role in accumulation of 
eosinophils in allergic reactions. Sagara et al.18 showed that a 
mAb against VLA-4 inhibited the late asthmatic response in sen-
sitized guinea pigs by inhibiting migration of eosinophils into the 
airway. Abraham et al.19 demonstrated that treatment with mAb 
against VLA-4 inhibited the late-phase asthmatic reaction (LAR) 
and airway hyper-responsiveness.
 The importance of the VLA-4/VCAM-1 pathway is also 
demonstrated in the clinical studies. Robinson et al.20 reported 
that the increased expression of IL-4 mRNA has been detected 
in the airways of patients with extrinsic asthma, and suggested 
the upregulation of VCAM-1 in the inflammatory site. Bentley et 
al.21 observed an increase in VCAM-1 expression in patients 
with asthma after antigen challenge, but no increase in ICAM-1 
was observed. They indicated highly significant correlations 
between VCAM-1 expression and infiltrated eosinophil number. 
Groves et al.22 observed that VCAM-1 was variably upregulated 
on dermal endothelium and dendritic cells in allergic contact 
dermatitis, atopic dermatitis, and psoriasis patients. These 
results, taken together, indicate that eosinophils selectively 
migrate into the allergic site via the VLA-4/VCAM-1 pathway. 
  Cetirizine was reported to selectively inhibit adhesion of 
eosinophils to HUVEC but the concentration which inhibited
adhesion was≧100μg/mL which is much higher than that used
in the usual clinical applications of cetirizine.23 None of the mast 
cell stabilizers tested in the present study showed selective inhibi-
tion of eosinophil adhesion at reasonable concentrations. DSCG 
did not inhibit adhesion even at 10-5mol/L; ketotifen inhibited 
adhesion only at 10-5mol/L; tranilast inhibited adhesion at 10-5 
and 10-6mol/L. These concentrations are higher than plasma 
concentrations of the drugs at clinical doses. TYB-2285 and its 
metabolites TC-286 and TC-326 inhibited eosinophil adhesion 
to endothelial cells at lower concentrations.
TYB-2285 and its metabolites did not inhibit neutrophil adhe-
sion. Eosinophils can adhere to endothelial cells via both X32-inte-
grin (such as Mac-1) and β1-integrin (such as VLA-4), however,
neutrophils express very low amounts of β1-integrins, so the β1-
integrin pathway is postulated to mediated selective eosinophil 
recruitment.5,24 Our blocking study with mAb against adhesion 
molecules revealed that the VLA-4/VCAM-1 pathway was domi-
nant in adhesion of eosinophils, and the Mac-1/ICAM-1 pathway 
was dominant in adhesion of neutrophils, in our adhesion assays. 
 We also examined the effect of anti-ICAM-1 on eosinophil 
adherence. The inhibitory effect of anti-ICAM-1 was similar to 
that for the inhibitory effect of anti-Mac-1 (data not shown). This
result also suggested that the β2-integrin/ICAM-1 pathway was
not dominant in adhesion of eosinophils. Ebisawa et al. indi-
cated that anti-VCAM-1 showed a stronger inhibitory effect in a
10min adhesion assay than in a 2h adhesion assay, suggesting 
that VLA-4 may be important in the initial adhesion of 
eosinophils.25 This finding also indicates the importance of the 
VLA-4/VCAM-1 pathway in our adhesion assay. Dobrin et al. 
showed eosinophil adherence to endothelial cells, and indi-
cated that anti-CD18 can block this adhesion.26 However, their 
assay involves adhesion induced by stimulation of eosinophils
with PMA, in contrast with ourTNF-α-stimulated model.
In an in vivo study, TYB-2285 given orally, inhibited accumula-
tion of eosinophils in broncho-alveolar lavage fluid (BALF) in
Brown Norway rats. Similar results have been obtained by the
administration of anti-VLA-4 (T Tominaga et al., unpubl. data).
This finding, together with those of the present study, suggest that
TYB-2285 and its metabolites TC-286 and TC-326 inhibit adhe-
sion of eosinophils to HUVEC by selective inhibition via the VLA-
4/VCAM-1 pathway. The mechanism of action of TYB-2285 is
not clear. Recently we suggested that tyrosine phosphorylation of
ppl25 focal adhesion kinase plays an important role in VLA-4-
mediated T cell costimulation.27 Further studies are required to
determine the precise mechanism of eosinophil adhesion.
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